Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $114.88 million flowed into the stock on the tick-up and $218.28 million flowed out of the stock on the tick-down, for a money net flow of $103.40 million out of the stock. Of all equities tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $4.12 for the day and closed at $177.77

AMGN has been the subject of several research reports. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $180.00 price target on shares of Amgen in a research report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on shares of Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $186.04.

The stock has a market capitalization of $130.40 billion, a price-to-earnings ratio of 16.28 and a beta of 1.35. The stock has a 50 day moving average of $173.78 and a 200 day moving average of $168.57.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 EPS. On average, equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.

Large investors have recently modified their holdings of the stock. Oakmont Partners LLC purchased a new stake in shares of Amgen during the first quarter worth $989,000. Honkamp Krueger Financial Services Inc. raised its position in Amgen by 4.7% in the first quarter. Honkamp Krueger Financial Services Inc. now owns 5,327 shares of the medical research company’s stock valued at $874,000 after buying an additional 239 shares during the last quarter. Private Trust Co. NA raised its position in Amgen by 16.4% in the first quarter. Private Trust Co. NA now owns 7,092 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 999 shares during the last quarter. Prospera Financial Services Inc raised its position in Amgen by 36.6% in the first quarter. Prospera Financial Services Inc now owns 2,829 shares of the medical research company’s stock valued at $462,000 after buying an additional 758 shares during the last quarter. Finally, First Command Financial Services Inc. raised its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the last quarter. 78.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/02/traders-sell-shares-of-amgen-inc-amgn-on-strength-amgn-2.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).